ETF Building Blocks ChannelPfizer Vaccine Should Work Against Omicron, Just Less EfficientlyBy Karrie GordonNovember 30, 2021
Nasdaq Investment Intelligence ChannelPfizer’s COVID-19 Pill 89% Effective in Those With Positive DiagnosisBy Karrie GordonNovember 5, 2021
Core Strategies ChannelFDA Gives Go-Ahead for Pfizer’s Vaccine for Kids 5–11, Waiting on CDC ApprovalBy Karrie GordonOctober 29, 2021
FeaturedBiotech ETFs Are Already Benefitting from Pfizer Vaccine’s Full ApprovalBy Ian YoungAugust 23, 2021
Nasdaq Investment Intelligence ChannelPfizer Reports Positive Earnings, Raises Forecasted Sales of VaccineBy Karrie GordonJuly 28, 2021
FeaturedAs U.K. Authorizes Pfizer Vaccine, Biotech ETFs Continue to RallyBy Ian YoungDecember 3, 2020
Equity ETF ChannelBiotech ETFs Poised for Gains after Moderna Vaccine NewsBy Ian YoungNovember 16, 2020
